TMCnet News

Global Cancer Immunotherapy Markets Report 2017 - Research and Markets
[September 25, 2017]

Global Cancer Immunotherapy Markets Report 2017 - Research and Markets


The "Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes" report has been added to Research and Markets' offering.

As discussed in this report, researchers have found that checkpoint inhibitors produce tumor responses by reactivating TILs (tumor infiltrating lymphocytes)especially CD8+ cytotoxic T cells. This key observation is perhaps the most important factor driving development of second-wave immuno-oncology strategies. As a result, researchers have been developing biomarkers that distinguish inflamed (i.e., TIL-containing) tumors - which are susceptible to checkpoint inhibitor therapy - from cold tumors, which are not. They have also been working to develop means to render cold tumors inflamed, via treatment with various conventional therapies and/or development of novel agents. These studies are the major theme of second-wave immuno-oncology, or immuno-oncology 2.0.

Moreover, treatment of advanced melanoma (the cancer for which the largest amount of data on immunotherapy has been amassed) with checkpoint inhibitors has in some cases produced spectacular results. For example, data released at the May 2016 ASCO Annual Meeting indicate that 40% of metastatic melanoma patients who received pembrolizumab (Merck's Keytruda) in a large clinical trial are still alive three years later. is represents a substantial improvement over just a few years ago, when the average survival time for patients with advanced melanoma was measured in months. Nevertheless, metastatic melanoma remains incurable.

Furthermore, in many studies in advanced melanoma and other cancers, only a minority of patients have benefited from immunotherapy treatments. Researchers and companies are therefore looking for ways to build on the initial successes of the immuno-oncology field to improve outcomes for more patients, hence the need for an immuno-oncology 2.0. Agents that are intended to improve the results of treatent with agents like checkpoint inhibitors may also be referred to as second-wave immuno-oncology agents.



Highlights of this Report Include:

  • Approvals of checkpoint inhibitors
  • Biomarkers for checkpoint inhibitor treatments
  • Approved and clinical-stage immunotherapy biologics other than checkpoint inhibitors
  • Immunotherapy with TIL cells
  • Commercialization of TIL therapy
  • Adoptive immunotherapy with genetically engineered T cells bearing chimeric antigen receptors (CARs)
  • Manufacturing issues with CAR T-cell therapies
  • General conclusions on the progress of cellular immunotherapy
  • Outlook for cancer immunotherapy

What you will Learn:


  • Why is immuno-oncology important, in terms of advancing cancer treatment beyond the traditional modalities of chemotherapy, radiation therapy, and surgery? What is immuno-oncology 2.0, and how might it advance the field of cancer immunotherapy?
  • What are the major classes of current and emerging immuno-oncology therapeutics?
  • How do these agents work?
  • Which immuno-oncology drugs have been approved? Which late-stage agents are likely to reach the market in the next 5 years? How might these newer agents benefit patients?
  • How are researchers, physicians, and companies attempting to achieve improved results with immuno-oncology treatments, in terms of increasing the numbers of patients who benefit from these treatments, achieving improved patient survival, and treating previously untreatable and incurable types of cancer?
  • Why has there been such a high rate of failure in the field of therapeutic anticancer vaccines? How are researchers and companies attempting to use immuno-oncology 2.0 strategies to reduce the numbers of failures, and thus to benefit patients?
  • Why is neoantigen science important in immuno-oncology, especially in development of novel vaccines and cellular immunotherapies? Which academic research groups, and established and emerging companies, are developing neoantigen-based therapies?
  • What are the cellular immunotherapy products that are emerging in 2017? What are the issues in manufacturing cellular immunotherapy products, and in administering them to patients safely? Why has it been difficult to commercialize tumor infiltration lymphocyte (TIL) therapies, despite their success in treating metastatic melanoma?
  • What is the expected market size for cancer immunotherapy in the 2017-2024 period? How might that market size be affected by the entry of new immuno-oncology 2.0 agents, and of cellular immunotherapy products?

Companies Mentioned

  • Aduro Biotech
  • Amgen
  • Argos Therapeutics
  • Bavarian Nordic
  • Bellicum Pharmaceuticals
  • bluebird bio
  • Celldex
  • Cellectis
  • Dendreon
  • Genelux
  • Genentech
  • Juno Therapeutics
  • Kite Pharma
  • MacroGenics
  • MedImmune
  • Nektar Therapeutics
  • Novartis
  • Regeneron
  • Roche
  • Sydys Corporation
  • TapImmune
  • Valeant
  • Xencor

For more information about this report visit https://www.researchandmarkets.com/research/zh84d4/cancer


[ Back To TMCnet.com's Homepage ]